Kroeger Smith M B, Rouzer C A, Taneyhill L A, Smith N A, Hughes S H, Boyer P L, Janssen P A, Moereels H, Koymans L, Arnold E
ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Maryland 21702, USA.
Protein Sci. 1995 Oct;4(10):2203-22. doi: 10.1002/pro.5560041026.
Computer modeling studies have been carried out on three nonnucleoside inhibitors complexed with human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), using crystal coordinate data from a subset of the protein surrounding the binding pocket region. Results from the minimizations of solvated complexes of 2-cyclopropyl-4-methyl-5,11-dihydro-5H-dipyrido[3,2-b :2',3'-e][1,4] diazepin-6-one (nevirapine), alpha-anilino-2, 6-dibromophenylacetamide (alpha-APA), and 8-chloro-tetrahydro-imidazo(4,5,1-jk)(1,4)-benzodiazepin-2(1H)-thi one (TIBO) show that all three inhibitors maintain a very similar conformational shape, roughly overlay each other in the binding pocket, and appear to function as pi-electron donors to aromatic side-chain residues surrounding the pocket. However, side-chain residues adapt to each bound inhibitor in a highly specific manner, closing down around the surface of the drug to make tight van der Waals contacts. Consequently, the results from the calculated minimizations reveal that only when the inhibitors are modeled in a site constructed from coordinate data obtained from their particular RT complex can the calculated binding energies be relied upon to predict the correct orientation of the drug in the pocket. In the correct site, these binding energies correlate with EC50 values determined for all three inhibitors in our laboratory. Analysis of the components of the binding energy reveals that, for all three inhibitors, solvation of the drug is endothermic, but solvation of the protein is exothermic, and the sum favors complex formation. In general, the protein is energetically more stable and the drug less stable in their complexes as compared to the reactant conformations. For all three inhibitors, interaction with the protein in the complex is highly favorable. Interactions of the inhibitors with individual residues correlate with crystallographic and site-specific mutational data. pi-Stacking interactions are important in binding and correlate with drug HOMO RHF/6-31G* energies. Modeling results are discussed with respect to the mechanism of complex formation and the design of nonnucleoside inhibitors that will be more effective against mutants of HIV-1 RT that are resistant to the currently available drugs.
利用结合口袋区域周围蛋白质子集的晶体坐标数据,对三种与1型人类免疫缺陷病毒(HIV-1)逆转录酶(RT)复合的非核苷抑制剂进行了计算机建模研究。对2-环丙基-4-甲基-5,11-二氢-5H-二吡啶并[3,2-b:2',3'-e][1,4]二氮杂卓-6-酮(奈韦拉平)、α-苯胺基-2,6-二溴苯乙酰胺(α-APA)和8-氯-四氢-咪唑并(4,5,1-jk)(1,4)-苯并二氮杂卓-2(1H)-硫酮(替博韦)的溶剂化复合物进行最小化处理的结果表明,所有三种抑制剂都保持非常相似的构象形状,在结合口袋中大致相互重叠,并且似乎作为π电子供体与口袋周围的芳香族侧链残基相互作用。然而,侧链残基以高度特异性的方式适应每个结合的抑制剂,在药物表面周围闭合以形成紧密的范德华接触。因此,计算得到的最小化结果表明,只有当抑制剂在由从其特定RT复合物获得的坐标数据构建的位点中进行建模时,计算得到的结合能才能可靠地预测药物在口袋中的正确取向。在正确的位点,这些结合能与我们实验室测定的所有三种抑制剂的EC50值相关。对结合能成分的分析表明,对于所有三种抑制剂,药物的溶剂化是吸热的,但蛋白质的溶剂化是放热的,并且两者之和有利于复合物的形成。一般来说,与反应物构象相比,蛋白质在其复合物中能量上更稳定,而药物则不太稳定。对于所有三种抑制剂,它们在复合物中与蛋白质的相互作用非常有利。抑制剂与单个残基的相互作用与晶体学和位点特异性突变数据相关。π-堆积相互作用在结合中很重要,并且与药物的HOMO RHF/6-31G*能量相关。结合复合物形成机制以及对HIV-1 RT突变体更有效的非核苷抑制剂的设计,对建模结果进行了讨论;这些突变体对目前可用的药物具有抗性。